Evaluating drug interaction potential from cytokine release syndrome using a physiologically based pharmacokinetic model: A case study of teclistamab

• المؤلفون الرئيسيون: Marie‐Emilie Willemin (مؤلف), Shun Xin Wang Lin (مؤلف), Loeckie De Zwart (مؤلف), Liviawati S. Wu (مؤلف), Xin Miao (مؤلف), Raluca Verona (مؤلف), Arnob Banerjee (مؤلف), Baolian Liu (مؤلف), Rachel Kobos (مؤلف), Ming Qi (مؤلف), Daniele Ouellet (مؤلف), Jenna D. Goldberg (مؤلف), Suzette Girgis (مؤلف)
• التنسيق: كتاب
• منشور في: Wiley, 2024-07-01T00:00:00Z.
• الموضوعات: article
• الوصول للمادة أونلاين: Connect to this object online.

Abstract Cytokine release syndrome (CRS) was associated with teclistamab treatment in the phase I/II MajesTEC‐1 study. Cytokines, especially interleukin (IL)‐6, are known suppressors of cytochrome P450 (CYP) enzymes' activity. A physiologically based pharmacokinetic model evaluated the impact o...